Vera Financial Statements From 2010 to 2025

VERA Stock  USD 28.07  0.08  0.29%   
Vera Therapeutics financial statements provide useful quarterly and yearly information to potential Vera Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Vera Therapeutics financial statements helps investors assess Vera Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Vera Therapeutics' valuation are summarized below:
Market Capitalization
1.8 B
Earnings Share
(2.75)
We have found one hundred twenty available fundamental trend indicators for Vera Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Vera Therapeutics current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 2.2 B. The current year's Enterprise Value is expected to grow to about 2.2 B
Check Vera Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vera Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 800, Net Interest Income of 13.7 M or Interest Income of 21.7 M, as well as many indicators such as Price To Sales Ratio of 282, Dividend Yield of 0.0 or PTB Ratio of 3.18. Vera financial statements analysis is a perfect complement when working with Vera Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Vera Therapeutics Correlation against competitors.
For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.

Vera Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets688.5 M655.7 M115.2 M
Slightly volatile
Short and Long Term Debt Total57.4 M54.6 M12.7 M
Slightly volatile
Other Current Liabilities17 M16.2 M3.8 M
Slightly volatile
Total Current Liabilities15.5 M25.4 M6.8 M
Slightly volatile
Other Liabilities244.5 K257.4 K761.1 K
Pretty Stable
Current Deferred Revenue499.9 K613 K437.8 K
Slightly volatile
Accounts Payable6.1 M7.7 M2.7 M
Slightly volatile
Cash71.4 M92.6 M30.6 M
Slightly volatile
Non Current Assets Total3.1 M4.5 M2.3 M
Slightly volatile
Non Currrent Assets Other124.5 K131 K153.7 K
Slightly volatile
Other Assets0.860.9332 K
Slightly volatile
Cash And Short Term Investments672.9 M640.9 M109.6 M
Slightly volatile
Common Stock Shares Outstanding28.1 M55.3 M13.2 M
Slightly volatile
Short Term Investments575.6 M548.2 M81.9 M
Slightly volatile
Liabilities And Stockholders Equity688.5 M655.7 M115.2 M
Slightly volatile
Non Current Liabilities Total43 M53.2 M45.8 M
Pretty Stable
Other Current Assets6.6 M10.4 M2.7 M
Slightly volatile
Other Stockholder Equity1.1 BB195.2 M
Slightly volatile
Total Liabilities74.6 M78.5 M53.7 M
Slightly volatile
Total Current Assets683.8 M651.2 M112.8 M
Slightly volatile
Net Working Capital657.1 M625.8 M105.3 M
Slightly volatile
Short Term Debt2.1 M1.5 M1.1 M
Slightly volatile
Common Stock67.2 K64 K16.8 K
Slightly volatile
Property Plant Equipment43.6 K45.9 K889.6 K
Slightly volatile
Net Receivables41.6 K46.8 K51 K
Slightly volatile
Inventory377.6 K424.8 K463.1 K
Slightly volatile
Non Current Liabilities Other2.6 M4.7 M2.2 M
Slightly volatile
Long Term Debt35.8 M50.7 M13.8 M
Slightly volatile
Common Stock Total Equity26.9 K32.2 K22.9 K
Slightly volatile
Long Term Debt Total16.4 M28.5 M9.6 M
Slightly volatile
Capital Surpluse266.1 M333.7 M219 M
Slightly volatile

Vera Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision800900981
Slightly volatile
Interest Income21.7 M20.7 M3.3 M
Slightly volatile
Interest ExpenseM7.6 M1.3 M
Slightly volatile
Selling General Administrative43 M41 M11.9 M
Slightly volatile
Other Operating Expenses63.4 M117.3 M35.9 M
Slightly volatile
Research Development63.9 M126.2 M29.9 M
Slightly volatile
Total Operating Expenses175.5 M167.2 M46 M
Slightly volatile
Selling And Marketing Expenses1.8 MM2.2 M
Slightly volatile

Vera Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation21.8 M20.8 M4.3 M
Slightly volatile
Begin Period Cash Flow44.2 M45.7 M25.8 M
Slightly volatile
Change To Account Receivables127.2 K143.1 K156 K
Slightly volatile
End Period Cash Flow58.6 M92.6 M25.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio282317346
Slightly volatile
Stock Based Compensation To Revenue4.945.566.0571
Slightly volatile
EV To Sales286321350
Slightly volatile
Inventory Turnover0.420.480.5216
Slightly volatile
Days Of Inventory On Hand549618674
Slightly volatile
Sales General And Administrative To Revenue10.2211.512.5356
Slightly volatile
Research And Ddevelopement To Revenue33.6137.8141.2236
Slightly volatile
Capex To Revenue0.0270.03050.0332
Slightly volatile
Cash Per Share12.1611.58313.8781
Slightly volatile
Income Quality0.650.88520.8321
Slightly volatile
Current Ratio26.9525.66788.2599
Slightly volatile
Capex Per Share0.01860.01760.0271
Slightly volatile
Revenue Per Share0.03490.03920.0428
Slightly volatile
Interest Debt Per Share0.490.84970.289
Slightly volatile
Debt To Assets0.0960.08330.0642
Slightly volatile
Operating Cycle549618674
Slightly volatile
Ebt Per Ebit1.070.91010.9863
Pretty Stable
Long Term Debt To Capitalization0.140.08430.0994
Slightly volatile
Quick Ratio26.9525.66788.2476
Slightly volatile
Net Income Per E B T1.11.01.0063
Slightly volatile
Cash Ratio3.473.65164.7782
Pretty Stable
Days Of Inventory Outstanding549618674
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.00721.0146
Pretty Stable
Fixed Asset Turnover0.490.550.6008
Slightly volatile
Debt Ratio0.0960.08330.0642
Slightly volatile
Price Sales Ratio282317346
Slightly volatile
Asset Turnover0.00850.00950.0104
Slightly volatile

Vera Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.2 B2.1 B874.6 M
Slightly volatile
Enterprise Value2.2 B2.1 B806.5 M
Slightly volatile

Vera Fundamental Market Drivers

Cash And Short Term Investments640.9 M

Vera Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Vera Therapeutics Financial Statements

Vera Therapeutics stakeholders use historical fundamental indicators, such as Vera Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Vera Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Vera Therapeutics' assets and liabilities are reflected in the revenues and expenses on Vera Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Vera Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue613 K499.9 K
Cost Of Revenue-1.7 M-1.6 M
Stock Based Compensation To Revenue 5.56  4.94 
Sales General And Administrative To Revenue 11.50  10.22 
Research And Ddevelopement To Revenue 37.81  33.61 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.04  0.03 
Ebit Per Revenue(49.31)(51.77)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Vera Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vera Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vera Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vera Therapeutics Stock:
Check out the analysis of Vera Therapeutics Correlation against competitors.
For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.75)
Return On Assets
(0.25)
Return On Equity
(0.45)
The market value of Vera Therapeutics is measured differently than its book value, which is the value of Vera that is recorded on the company's balance sheet. Investors also form their own opinion of Vera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vera Therapeutics' market value can be influenced by many factors that don't directly affect Vera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.